Nexium / Losec Kidney Disease Canadian Class Action

+ - Documents (4)

CONSUMER LAW GROUP is investigating a Canada-wide class action lawsuit against AstraZeneca, the maker of the proton pump inhibitors (PPIs) Nexium and Losec, on behalf of individuals who developed kidney (renal) disease after taking either or both of the drugs.

Nexium [the brand name of the medication esomeprazole] and Losec [the brand name of the medication omeprazole] are prescribed to thousands of people in Canada to treat:

- Peptic Ulcer Disease (i.e. stomach ulcers)
- Gastroesophageal Reflux Disease (GERD)
- Zollinger-Ellison Syndrome (i.e. duodenal ulcers)
- Heartburn and other acid issues.

Several scientific studies published in medical journals have confirmed that there is a significant increased risk of developing kidney disease when taking Nexium and/or Losec:

• On April 2, 2015, the medical journal, the Canadian Medical Association Journal, published a study that concluded that the use of proton pump inhibitors resulted in higher rates of acute kidney injury (AKI) and acute interstitial nephritis (AIN) in older patients.

• On January 11, 2016, the medical journal, JAMA Internal Medicine, published a study that linked the use of a proton pump inhibitor with a 20% to 50% higher risk for incident chronic kidney disease (CKD).

• In March 2016, the medical journal, the American Society of Nephrology, published a study that found that proton pump inhibitor users were more likely to experience kidney function decline than those taking H2 receptor blockers and that they also had a 28% increased risk of developing chronic kidney disease and a 96% increased risk of developing kidney failure.

Neither Nexium’s nor Losec's labels nor product monographs have ever warned Canadian patients of any potential relationship between kidney disease and taking the drug(s).

Many patients suffering from this problem eventually have to go on dialysis or even undergo a kidney transplant. The most commonly reported kidney diseases include:

- acute kidney injury (AKI)
- acute interstitial nephritis (AIN)
- chronic interstitial nephritis (CIN)
- chronic kidney disease (CKD)
- and end stage renal disease (ESRD).

The class action lawsuit identifies the group of affected persons as:

All persons residing in Canada who have taken and/or purchased the proton pump inhibitor drug, ESOMEPRAZOLE (sold under the brand name NEXIUM®) and/or OMEPRAZOLE (sold under the brand name LOSEC®) and their successors, assigns, family members, and dependants, or any other group to be determined by the Court.

If you or a member of your family have used the drugs Nexium and/or Losec and were subsequently diagnosed with kidney disease, and you wish more information on potential compensation or to be kept advised of the status of the Nexium and Losec Drug Side Effects Class Action litigation or any resulting compensation from the Nexium and Losec Drug Side Effects Lawsuit in Canada, Quebec or Ontario, please provide your contact information to our law firm using the below form.

IF YOU WISH TO JOIN THE CLASS ACTION OR TO SIMPLY GET MORE INFORMATION, PLEASE COMPLETE THE FORM BELOW. Please note that providing your information creates no financial obligation for you. You are not charged any fee or cost for joining this class action. Our law firm is paid a contingency fee from the compensation recovered, only if the class action is successful. All information contained in this transmission is confidential and Consumer Law Group agrees to protect this information against unauthorized use, publication or disclosure.